Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients

AiCuris AG, a German biotech company, is currently recruiting for their clinical trial on Pritelivir. Pritelivir is a highly anticipated new treatment for resistant Herpes Simplex Virus infections that cannot be managed with the available anti-virals. It is currently being tested for immune compromised patients only and, if proven safe and effective, could become a new treatment option for this population.

Link here with more details on criteria and how to apply.

Patients they are recruiting for:

Group C: For patients that are immune compromised and Acyclovir resistant

Group D: For patients that are immune compromised and present (or develop through the course of trials) foscarnet resistance/intolerance

Group E: For patients that are immune compromised but are responsive to Acyclovir

There are additional inclusion and exclusion criteria so please check the trial page on on the link above.

Not all centers are already open and recruiting so if the one in your area is not recruiting yet you may want to contact them to be added to a waitlist.

Testing locations:

  • Los Angeles, California
  • New Haven, Connecticut
  • DeLand, Florida
  • For Pierce, Florida
  • Atlanta, Georgia
  • Chicago, Illinois
  • Baton Rouge, Louisiana
  • Baltimore, Maryland
  • Boston, Massachusetts
  • Detroit, Michigan
  • Pittsburgh, Pennsylvania
  • Houston, Texas
  • Seattle, Washington

Get in touch

Stay informed of the latest research news and advocacy updates. Sign up for Herpes Cure Advocacy news!

Questions? Email us:

Leave a Reply